Synairgen Regulatory News (SNG)

Synairgen plc

('Synairgen' or the 'Company')

Board Changes

Southampton, UK - 1 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the appointment of Amanda Radford FCA to the Board as an independent Non-Executive Director and Chair of the Audit Committee.

Amanda is an internationally experienced finance leader with substantial listed company expertise and is currently the Group Financial Controller of BSI Group, the global B2B company which employs around 5,500 people and generates revenues of c. £600M. Over the course of her career, Amanda has held senior finance roles in a number of public companies and has significant experience in external reporting, financial controls, forecasting and business planning as well as M&A and fundraising. She has previously held senior positions at companies including Convatec Group plc, Post Office Ltd, Pets at Home Vet Group and TalkTalk Telecom Group.

Starting her career as a qualified chartered accountant, Amanda trained at Deloitte prior to which she received a BSc in Biochemistry with Molecular & Cell Biology from Birmingham University.

Synairgen, furthermore, announces that, after 12 years of service, Iain Buchanan has retired from the Board and as Chair of the Remuneration and Nomination Committee. Felicity ('Flic') Gabbay succeeds Iain as Chair of the Remuneration and Nomination Committee.

Simon Shaw, Chair of Synairgen, said: "On behalf of the Board, and personally, I would like to thank Iain for his 12 years of unstinting service and support to the Board and the Committees on which he served.

"I would also like to welcome Amanda, whose wealth of experience will be invaluable to the Synairgen Board as we continue to focus on the clinical development of SNG001."

Relevant disclosures

The following disclosures are required under Schedule Two, paragraph (g) of the AIM Rules for Companies:

Mrs Amanda Dawn Radford, aged 52, holds no current directorships, but has held the following directorships and/or partnerships in the past five years:

Past directorships:

· ConvaTec Finance Holdings Limited

· ConvaTec International U.K. Limited

· ConvaTec Holdings U.K. Limited

· British Eventing Limited

Amanda does not have any beneficial interest in the ordinary shares of the Company.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR').

For further enquiries, please contact:

Synairgen plc

Brooke Clarke, Head of Communications

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Charlie Beeson (Corporate Finance)

Alice Lane, Sunila de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

cscsynairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com

Tel: +1 516-606-6545

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.